Jiangxi Jemincare to Start US Trial of SARS-CoV-2 Neutralizing Antibody

Jiangxi Jemincare Group was approved to start US clinical trials of its SARS-CoV-2 neutralizing antibody, JMB2002, which was developed by the Jemincare Shanghai Research Center . The company published data in February showing that, in preclinical studies, JMB2002 showed strong prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques. In January, Jemincare started a China Phase I clinical trial of the candidate in healthy volunteers. The company is headquartered in Nanchang . More details.... Share this with colleagues: // //